![]() |
|
|
Vol. 288, Issue 3, 1002-1014, March 1999
Institut de Recherches Servier, Centre de Recherches de Croissy,
Psychopharmacology Department, Croissy-sur-Seine, Paris, France
S-16924 is a potential antipsychotic that displays agonist and
antagonist properties at serotonin (5-HT)1A and
5-HT2A/2C receptors, respectively. In a pigeon conflict
procedure, the benzodiazepine clorazepate (CLZ) increased punished
responses, an action mimicked by S-16924, whereas the atypical
antipsychotic clozapine and the neuroleptic haloperidol were inactive.
Similarly, in a Vogel conflict paradigm in rats, CLZ increased punished
responses, an action shared by S-16924 but not by clozapine or
haloperidol. This action of S-16924 was abolished by the
5-HT1A antagonist WAY-100,635. Ultrasonic vocalizations in
rats were inhibited by CLZ, S-16924, clozapine, and haloperidol.
However, although WAY-100,635 abolished the action of S-16924, it did
not affect clozapine and haloperidol. In a rat elevated plus-maze, CLZ,
but not S-16924, clozapine, and haloperidol, increased open-arm
entries. Like CLZ, S-16924 increased social interaction in rats,
whereas clozapine and haloperidol were inactive. WAY-100,635 abolished
this action of S-16924. CLZ, S-16924, clozapine, and haloperidol
decreased aggressive interactions in isolated mice, but this effect of
S-16924 was not blocked by WAY-100,635. All drugs inhibited motor
behavior, but the separation to anxiolytic doses was more pronounced
for S-16924 than for CLZ. Finally, in freely moving rats, CLZ and
S-16924, but not clozapine and haloperidol, decreased dialysis levels
of 5-HT in the nucleus accumbens: this action of S-16924 was blocked by
WAY-100,165. In conclusion, in contrast to haloperidol and clozapine,
S-16924 possessed a broad-based profile of anxiolytic activity at doses lower than those provoking motor disruption. Its principal mechanism of
action was activation of 5-HT1A (auto)receptors.
This article has been cited by other articles:
![]() |
M. J. Millan, M. Brocco, J.-M. Rivet, V. Audinot, A. Newman-Tancredi, L. Maiofiss, S. Queriaux, N. Despaux, J.-L. Peglion, and A. Dekeyne S18327 (1-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at alpha 1- and alpha 2-Adrenergic Receptors: II. Functional Profile and a Multiparametric Comparison with Haloperidol, Clozapine, and 11 Other Antipsychotic Agents J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 54 - 66. [Abstract] [Full Text] |
||||